文献

J-GLOBAL ID：201802252850767846   整理番号：18A1496109

PCSK9阻害剤の適切な臨床使用のための声明

Statement for Appropriate Clinical Use of PCSK9 Inhibitors

著者 (10件)： Nohara Atsushi (Kanazawa University Health Service Center) ,  Ohmura Hirotoshi (Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine) ,  Okazaki Hiroaki (Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo) ,  Ogura Masatsune (Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute) ,  Kitagawa Kazuo (Department of Neurology, Tokyo Women’s Medical University) ,  Koseki Masahiro (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine) ,  Sato Kayoko (Department of Cardiology, Tokyo Women’s Medical University) ,  Tsukamoto Kazuhisa (Department of Internal Medicine, Teikyo University School of Medicine) ,  Yamashita Shizuya (Rinku General Medical Center) ,  Yamashita Shizuya (Department of Community Medicine & Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine)
資料名： Journal of Atherosclerosis and Thrombosis (Web)  (Journal of Atherosclerosis and Thrombosis (Web))
巻： 25  号： 8  ページ： 747-750(J-STAGE)  発行年： 2018年 
JST資料番号： U0153A  ISSN： 1880-3873  資料種別： 逐次刊行物 (A)
記事区分： 解説  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： ・PCSK9阻害剤は強力な血中LDLコレステロール(LDL-...

シソーラス用語： ペプチド結合ヒドロラーゼ ,...
準シソーラス用語： 医療経済 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1496109&from=J-GLOBAL&jstjournalNo=U0153A") }}

著者キーワード (3件)： 声明 ,  適切な臨床使用 ,  PCSK9阻害剤

分類 (3件)： 薬事,薬業  (GU01020R) ,  代謝異常・栄養性疾患の治療  (GD05030F) ,  循環系疾患の薬物療法  (GJ05020M)

引用文献 (6件)：

• 1) Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovacular Diseases, 2017 (in Japanese)
• 2) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, for the FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722
• 3) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS: Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease. Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 2017; 137: 338-350
• 4) Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoğlu L, Bax JJ, Catapano AL: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J, 2017, ehx549. doi: 10.1093/eurheartj/ehx549
• 5) Harada-Shiba M, Ohta T, Ohtake A, Ogura M, Dobashi K, Nohara A, Yamashita S, Yokote K: Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia. J Atheroscler Thromb, 2018; 25: 539-553

タイトルに関連する用語 (3件)： PCSK9阻害剤 ,  臨床 ,  声明